Did you know?
ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.
Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!
Over $10B invested in last 18 months! Download free report on life science investment in China.
The Week in Review: Reckitt Benckiser Buys Anhui’s Golong Medicine
Deals and Financings
Reckitt Benckiser, a British maker of OTC drugs and home products, has bought Golong Medicine of Anhui, a TCM company known for its sore-throat treatment Man Yan Shu Ning (see story). The British company wants to expand its distribution foothold in China as a way to increase revenues from its extensive list of products. It does not intend to take Man Yan Shu Ning to the west. Financial details of the transaction were not disclosed.
Government and Regulatory
China’s SFDA has announced a set of newly-revised regulations for the country’s drug distributors (see story). These new Good Supply Practices (GSP) for drugs, which comprise 187 articles, will promote higher standards of protection for the country’s drug supply among wholesalers and retailers. An SFDA spokesperson also said the government wants to reduce the number of China’s drug wholesalers from a current 13,000 to just 3,000, a draconian rollup of the country’s highly fragmented distribution system.
Trials and Approvals
Sihuan Pharma (HK: 0460) received permission from the SFDA to begin clinical trials of pinoxacin hydrochloride, a Category 1.1 innovative drug (see story). The drug is a DPP-4 inhibitor that is intended for type 2 diabetics. Sihuan, a Beijing-based company, intends to start the Phase I trial during the first half of 2013. In January, Sihuan announced approval to begin clinical trials of another Category 1.1 drug, an innovative carbapenem antibiotic known as benapenum. So far, four of Sihuan’s Category 1 drugs have received approval for human testing.
Regeneron Pharma (NSDQ: REGN) and Bayer (Xetra: BAY) have started a new Phase III trial to test Eylea® (aflibercept) Injection as a treatment for Diabetic Macular Edema (DME) (see story). The trial will be conducted in China, Russia and other Asian countries. In its global Phase II DME program, Eylea showed promising results.
Luye Pharma Group (SGX: A61) reported its Xuezhikang drug, a TCM used to lower cholesterol, proved efficacy in a US Phase II clinical trial (see story). According to the company, the drug “significantly” lowered low-density lipoprotein cholesterol while elevating beneficial high-density lipoprotein cholesterol. The company did not disclose specific results from the trial. Xuezhikang is the only TCM included in the National Basic List as a treatment for blood lipids.
Beijing Double-Crane Pharma (SHE: 600062) will invest 271 million RMB ($43 million) to build a fluid infusion manufacturing facility in Shanghai’s Jinshan Development Park (see story). The plant will be operated by a subsidiary of Double-Crane, Shanghai Changzheng Fumin Jinshan Pharmaceutical Co.